| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.09 | 0.003 |